Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 6, Issue 3, 2004, Pages 405-412

  Pfützner, Andreas ^a,b   Pfützner, Anke H ^a   Larbig, Martin ^c   Forst, Thomas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c Sciema Science and Marketing Llt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CARBOXYPEPTIDASE H; GLIMEPIRIDE; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; PROINSULIN;

EID: 3042690588     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091504774198124     Document Type: Review

References (60)

1. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-160.
2. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J: Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive during 9-1/2 year follow-up to the Helsinki Policemen Study population. Acta Med Scand Suppl 1985;701: 38-52.
3. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study 10 years later. Horm Metab Res Suppl 1985;15:41-46.
4. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-957.
5. Arrants J: Hyperinsulinemia and cardiovascular risk. Heart Lung 1994;23:118-122.
6. Tonomo S, Kato N, Utsugi T, Ohno T, Shimizu M, Fukuda M, Itoh Y, Ishii C, Kawazu S: The role of insulin in coronary atherosclerosis. Diabetes Res Clin Pract 1994;22:117-122.
7. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapää P: Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991;11:1068-1076.
8. Agewall S, Fagerbern B, Atavall S, Wendelhog I, Urbanavjejus V, Wikstamd J: Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995;26:956-960.
9. Bressler P, Bailey S, Matsuda M, DeFronzo RA: Insulin resistance and coronary artery disease. Diabetologia 1996;39:1345-1350.
10. Howard G, O'Leary DH, Zaccaro D, Haffner SM, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. Circulation 1996;93:1809-1817.
11. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA: Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype-a report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 1994;4:40-45.
12. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G: Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia 1992;35:766-770.
13. Ferrara A, Barett-Connor EL, Edelstein SL: Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol 1994;140:857-869.
14. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercouri M, Uusitupa M: Carotid artery intima media thickness and its determinants in elderly patients with NIDDM and in non-diabetic subjects. Stroke 1996;27:1986-1992.
15. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Werme D: Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes 1996;45:736-741.
16. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30: 698-702.
17. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y: Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1988;31:355-360.
18. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN: Insulin deficiency in non-insulin dependent diabetes. Lancet 1989;1: 293-295.
19. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowlyk S, Bennett PH, Porte D Jr: Disproportionately elevated proinsulin in Pima Indians with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1990;70:1247-1253.
20. Reaven GM, Chen Y-Di, Hollenbeck CB, Scheu WHH, Ostrega D, Polonsky KS: Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 1993;76:44-48.
21. Birkeland KI, Torjesen PA, Erikson J, Vaaler S, Groop L: Hyperproinsulinemia of type 2 diabetes is not present before the development of hyperglycemia. Diabetes Care 1994;17:1307-1310.
22. Haffner SM, Bowsher RR, Mykkänen L, Hazuda HP, Mitchell BD, Valdez RA, Gingerich R, Monterossa A, Stem MP: Proinsulin and specific insulin concentrations in high and low risk populations for type 2 diabetes. Diabetes 1994;43:1490-1493.
23. Kahn SE, Leonetti D, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY: Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity: clinical research center study. J Clin Endocrinol Metab 1995;80:1399-1406.
24. Båvenholm P, Proudler A, Tornvall P, Godsland I, Landau C, De Faire U, Hamsten A: Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995;92:1422-1429.
25. Yudkin JS, Denver AE, Mohamed-Ali V, Ramaiya KL, Nagi DK, Goubet S, McLarty DG, Swai A: The relationship of concentrations of insulin and pro insulin-like molecules with coronary heart disease prevalence and incidence: a study of two ethnic groups. Diabetes Care 1997;20:1093-1100.
26. Haffner SM, Gonzalez C, Mykkännen L, Stern M: Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion 2 diabetes: the Mexico City Diabetes Study. Diabetologia 1997;40:830-837.
27. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Ishii J, Shibazaki S, Nagai M, Kawazu S: A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabet Med 1996;13:330-336.
28. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Berstroem RW, Fujimoto WY: Proinsulin as a marker for the development of type 2 diabetes in Japanese-American men. Diabetes 1995;44:173-179.
29. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ: Fasting proinsulin and 2-h post-load glucose levels predict the conversion to type 2 diabetes in subjects with impaired glucose tolerance: the Hoorn study. Diabetologia 1996;39:113-118.
30. Wareham NJ, Byrne CD, Hales CN: Role of insulin and proinsulin in diabetic vascular disease. Metabolism 1995;44(Suppl 4):76-82.
31. Csorba TR: Proinsulin: biosynthesis, conversion, assay methods and clinical studies. Clin Biochem 1991;24:447-454.
32. Yudkin JS: Circulating proinsulin-like molecules. J Diabetes Complications 1993;7:113-123.
33. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46:1725-1732.
34. Nagi D, Ali VM, Walji S, Jain SK, Yudkin JS: Hyperinsulinemia in nondiabetic Asian subjects using specific assays for insulin, intact proinsulin, and des-31,32-proinsulin. Diabetes Care 1996;19:39-42.
35. Roder ME, Porte D, Schwartz RS, Kahn SE: Disproportionately elevated proinsulin levels reflect the degree of impaired β-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:604-608.
36. Mykkänen L, Haffner SM, Kuusito J, Pyorala K, Hales CN, Laakso M: Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia 1995;38:1176-1182.
37. Wareham NJ, Byrne CD, Williams R, Day NE, Hales CN: Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 1999;223:262-270.
38. Festa A, D'Agostino R, Mykkänen L, Tracy RP, Hales CN, Howard BV, Haffner SM: LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. Diabetes Care 1999;22:1688-1693.
39. Kubo K: Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes. Endocr J 2002;49:323-328.
40. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993;10:27-32.
41. Luzio SD, Lucas I, Owen DR: Importance of validation of immunoassays for intact proinsulin. Clin Chem Lab Med 2001;39:631-633.
42. Pfützner A, Kunt T, Löbig M, Knesovic M, Forst T: Clinical and laboratory evaluation characteristics of new chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med 2003;41:1234-1238.
43. Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Forst T: Fasting intact proinsulin is a highly specific indicator of insulin resistance in type 2 diabetes. Diabetes Care 2004; 27:682-687.
44. Pfützner A, Standl E, Schulze J, Pahler S, Larbig M, Lübben G, Forst T: Results from the IRIS-II study: high fasting output of un-cleaved intact proinsulin from the pancreatic β-cell is a specific marker for insulin resistance [abstract]. Diabetes 2003;52(Suppl 1):A542.
45. Hostens K, Ling Z, Van Schravendijk C, Pipeleers D: Prolonged exposure of human beta-cells to high glucose concentrations increases their release of proinsulin during acute stimulation with glucose or arginine. J Clin Endocrinol Metab 1999;84:1386-1390.
46. Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D Jr, Robertson RP: Hyperproinsulinemia is associated with increased beta-cell demand after hemipancreatectomy in humans. J Clin Invest 1996;97:455-460.
47. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR: Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 1993;42:1297-1302.
48. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey SG: Concentrations of proinsulin-like-molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly study. Diabetologia 2002;45:327-336.
49. Lindahl B, Dinesen B, Eliasson M, Roeder M, Jansson JH, Huhtasaari F, Hallmans G: High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism 1999;48:1197-1202.
50. Lindahl B, Dinesen B, Eliasson M, Roeder M, Hallmans G, Stegmayr B: High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 2000;31:2936-2941.
51. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH: Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992;15:666-692.
52. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-980.
53. Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM: Clinical features of unrecognised myocardial infarction-silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 1973;32:1-7.
54. Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y: Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes 1989;38:262-266.
55. Davies MJ, Metcalfe J, Day JL, Grenfall A, Hales CN, Gray IP: Improved beta-cell function, with reduction in secretion in intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabet Med 1994;11:71-78.
56. Nagi DK, Ali VM, Yudkin JS: Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996;13:753-757.
57. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP: Effect of sulphonylurea therapy on plasma insulin, intact proinsulin and 32/33 split proinsulin in subjects with diabetes mellitus. Diabet Med 1993;11:293-298.
58. Pfützner A, Langenfeld M, Hohberg C, Lübben G, Forst T: Impact of pioglitazone treatment on insulin resistance and fasting intact proinsulin concentrations [abstract]. Diabetes 2004;53(Suppl 1):P669.
59. Prigeon RL, Kahn SE, Porte D Jr: Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998;83:819-823.
60. Porter LE, Freed MI, Jones NP, Biswas N: Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes [abstract]. Diabetes 2000;49(Suppl 1):A122.